한국형 양극성 장애 약물치료 알고리듬 2022: 동반 신체질환 = Korean Medication Algorithm Project for Bipolar Disorder 2022: Comorbid Physical IllnessesKorean Medication Algorithm Project for Bipolar Disorder 2022: Comorbid Physical Illnesses

다국어 초록 (Multilingual Abstract)

Objectives The present study was carried out to revise the guidelines for the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) 2018. The revision was carried out based on expert opinions to facilitate clinical decisions related to the treatment of bipolar disorders in patients with comorbid physical illnesses.
Methods A 56-item questionnaire was developed; a consensus was arrived at by 87 out of 93 experts (93.5%), on the pharmacological treatment strategies to be used in cases of comorbid physical illnesses accompanying bipolar disorders.
Results For patients with bipolar disorder exhibiting comorbid conditions, by consensus, lamotrigine, aripiprazole, and ziprasidone were recommended as the first-line strategies for metabolic syndrome; lamotrigine and aripiprazole were the recommended first-line strategies for cardiovascular problems; lithium and aripiprazole were the recommended first-line strategies for haptic problems; valproate, lamotrigine, aripiprazole, and quetiapine were the recommended first-line strategies for renal problems; and valproate and aripiprazole were the recommended first-line strategies for cerebrovascular problems or cerebral damage.
Conclusion The present study is the most recent consensus among experts on recommendations for the treatment of bipolar disorders in patients with comorbid physical illnesses. Aripiprazole was recommended as the first-line pharmacotherapeutic agent in five comorbid physical conditions. This recommendation is similar to KMAP-BP 2018. Additionally, lamotrigine has been added as a first -line pharmacotherapeutic agent in patients with the metabolic syndrome, cardiovascular problems, and renal problems in the current algorithm.

참고문헌 (Reference)

1 송후림 ; 박원명 ; 윤보현 ; 전덕인 ; 서정석 ; 김원 ; 이정구 ; 우영섭 ; 정종현 ; 김문두 ; 손인기 ; 심세훈 ; 민경준, "한국형 양극성 장애 약물치료 알고리듬 2018 : 신체 질환이 동반되었을 경우" 대한우울조울병학회 16 (16): 129-133, 2018

2 윤보현 ; 박원명 ; 민경준 ; 김원 ; 김병수 ; 이정구 ; 주연호 ; 서정석 ; 이은 ; 안용민 ; 신영철 ; 우영섭 ; 배승오 ; 전덕인, "한국형 양극성 장애 약물치료 알고리듬 2010: 다른 치료 지침들과의 비교" 대한정신약물학회 22 (22): 171-182, 2011

3 박원명 ; 신영철 ; 전덕인 ; 윤보현 ; 김대진 ; 안용민 ; 권준수 ; 민경준, "양극성 장애의 한국형 약물치료 알고리듬" 대한정신약물학회 13 (13): 205-221, 2002

4 전덕인 ; 석정호 ; 최강 ; 윤형준 ; 조현상 ; 김세주 ; 이은, "양극성 장애 환자의 의학적 공존질환：후향적 챠트 조사" 대한우울조울병학회 5 (5): 30-33, 2007

5 Camm AJ, "Ziprasidone and the corrected QT interval : a comprehensive summary of clinical data" 26 : 351-365, 2012

6 Hasnain M, "Weight considerations in psychotropic drug prescribing and switching" 125 : 117-129, 2013

7 Robert S, "Traumatic brain injury and mood disorders" 10 : 335-345, 2020

8 Fountoulakis KN, "The International College of Neuro-Psychopharmacology (CINP)treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines" 20 : 180-195, 2017

9 McGirr A, "Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials" 3 : 1138-1146, 2016

10 Akiskal HS, "Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders" 59 (59): S5-S30, 2000

11 Telles-Correia D, "Psychotropic drugs and liver disease : a critical review of pharmacokinetics and liver toxicity" 8 : 26-38, 2017

12 Carney CP, "Medical comorbidity in women and men with bipolar disorders : a population-based controlled study" 68 : 684-691, 2006

13 Beyer J, "Medical comorbidity in a bipolar outpatient clinical population" 30 : 401-404, 2005

14 Reynolds GP, "Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment" 31 : 1430-1436, 2017

15 Bhagwagar Z, "Lamotrigine in the treatment of bipolar disorder" 6 : 1401-1408, 2005

16 Young Sup Woo ; Won-Myong Bahk ; Jung Goo Lee ; Jong Hyun Jeong ; Moon Doo Kim ; Inki Sohn ; Se-Hoon Shim ; Duk-In Jon ; Jeong Seok Seo ; Kyung Joon Min ; Won Kim ; 송후림 ; Bo-Hyun Yoon, "Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision" 대한정신약물학회 16 (16): 434-448, 2018

17 Salvador-Carulla L, "From the EBM pyramid to the Greek temple : a new conceptual approach to guidelines as implementation tools in mental health" 26 : 105-114, 2017

18 Hohmann E, "Expert opinion is necessary : Delphi panel methodology facilitates a scientific approach to consensus" 34 : 349-351, 2018

19 Goodwin GM, "Evidence-based guidelines for treating bipolar disorder:revised third edition recommendations from the British Association for Psychopharmacology" 30 : 495-553, 2016

20 Baptista T, "Drug induced weight gain, an impediment to successful pharmacotherapy:focus on antipsychotics" 5 : 279-299, 2004

21 Wootton R, "Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers" 43 : 23-27, 1997

22 Greger J, "Comparison of the metabolic characteristics of newer second generation antipsychotics: brexpiprazole, lurasidone, asenapine, cariprazine, and iloperidone with olanzapine as a comparator" 41 : 5-12, 2021

23 Miura T, "Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis" 1 : 351-359, 2014

24 Yatham LN, "Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD)2018 guidelines for the management of patients with bipolar disorder" 20 : 97-170, 2018

25 Baldessarini RJ, "Bipolar depression : a major unsolved challenge" 8 : 1-, 2020

26 Carli M, "Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences" 14 : 238-, 2021

27 Argo TR, "Aripiprazole, a novel atypical antipsychotic drug" 24 : 212-228, 2004

28 Levy RH, "Antiepileptic drugs" Raven Press 605-620, 1995

29 Hayes JF, "Adverse renal, endocrine, hepatic, and metabolic events during maintenance mood stabilizer treatment for bipolar disorder: a populationbased cohort study" 13 : e1002058-, 2016